Researchers assessed the severity of COVID-19 and thrombotic complications after COVID-19 vaccination in patients with high-risk antiphospholipid syndrome.
Researchers assessed the attainment of traditional cardiovascular risk factor therapeutic goals in patients with antiphospholipid syndrome vs those with rheumatoid arthritis and diabetes mellitus.
Using a large cohort over a period of 38 years, the researchers assessed thrombocytopenia and other clinical variables as predictors of outcomes in patients with antiphospholipid syndrome.
Jane Salmon, MD, takes us on a deep dive into identifying and predicting the risk for pregnancy complications in patients with lupus and APS.
Dual antiplatelet therapy may be effective for the prophylaxis of recurrent arterial thrombosis in patients with antiphospholipid syndrome.
Intrauterine fetal death may be an early sign of antiphospholipid syndrome in pregnant women.
Recent evidence links specific bacterial, viral infections, and vaccination to the development of APS, but these associations are not clear-cut.
The aPS/PT antibodies might represent markers of aPL-related pregnancy complications, such as intrauterine grown restriction and preeclampsia.
Many patients with antiphospholipid syndrome develop neurological disorders that appear to have a nonthrombotic pathogenesis.
A European League Against Rheumatism writing committee has issued recommendations for family planning for women with systemic lupus erythematosus and antiphospholipid syndrome based on a systemic review.
